Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amantadine plus methylphenidate for early consciousness recovery after traumatic brain injury
IRCT20130310012776N7Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of amantadine and methylphenidate in traumatic brain injury (TBI) (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoints: ICU length of stay, Average length of hospital stay and 4 more. Started Jan 2022; status: completed.
02
Drugs
amantadinemethylphenidate
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on IRCT20130310012776N7.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20130310012776N7.